Bladder cancer survival statistics

Coronavirus (COVID-19)

We know that this is an especially worrying time so we have created a key messages document for Health Professionals focussed on safety netting patients presenting with symptoms during the coronavirus outbreak. We have also created a page on the subject specifically for patients on our about cancer hub. We will update that information as guidance changes.

Safety netting patients during the COVID-19 pandemic recovery phase

Survival

Survive bladder cancer for 10 or more years, 2013-2017, England

Age

Age that bladder cancer survival is highest, 2009-2013, England

 

Improvement

Bladder cancer survival in the UK has increased in the last 40 years

 

77.8% of males survive bladder cancer for at least one year. This falls to 56.1% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with bladder cancer during 2013-2017 in England.[1] Survival for females at one year is 64.5% and falls to 43.9% surviving for at least five years. Survival for females is lower than for than for males at one year, and lower than for at five years.

Bladder Cancer Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England, 2013-2017

The bar chart shows one- and five-year net survival and predicted ten-year net survival, with 95% confidence intervals. Open a glossary item
 

Bladder cancer survival continues to fall beyond five years after diagnosis. 48.3% of males and 41.0% of females are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with bladder cancer during 2013-2017 in England.[1]

See also

Cancer survival statistics for common cancers in the UK

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.

About this data

Data is for England, 2013 - 2017, ICD-10 C67.

Survival statistics give an overall picture of survival and the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year survival for bladder cancer is generally higher in younger men and women and decreases with increasing age. Five-year net survival in men ranges from 73% in 15-49 year-olds to 43% in 80-99 year-olds for patients diagnosed with bladder cancer in England during 2009-2013.[1] In women, five-year survival ranges from 57% in 50-59 year-olds to 31% in 80-99 year-olds.

Bladder Cancer (C67), Five-Year Net Survival by Age, England, 2009-2013

See also

Bladder cancer incidence statistics by age

Bladder cancer mortality statistics by age

Cancer survival statistics by age for all cancers

References

  1. Office for National Statistics. Cancer survival in England: adults diagnosed in 2009 to 2013 ,followed up to 2014. Newport: ONS; 2015.

About this data

Data is for: England, 2009-2013, ICD-10 C67

Last reviewed:

Bladder cancer survival trends are difficult to interpret because of changes to classification and coding practices affecting the definition of invasive carcinoma of the bladder.The decrease in bladder cancer survival since the 1990s is likely to be due to an increasing proportion of bladder tumours now being coded as in situ or uncertain.

One-year age-standardised Open a glossary itemnet survival for bladder cancer in men has increased from 63% during 1971-1972 to 80% during 1990-1991 and then decreased to 77% during 2010-2011 in England and Wales.[1] In women, one-year survival has increased from 53% to 70% and then decreased to 62% over the same time periods.

Bladder Cancer (C67), Age-Standardised One-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year age-standardised net survival for bladder cancer in men has increased from 41% during 1971-1972 to 63% during 1990-1991 and then decreased to a predicted survival of 57% during 2010-2011 in England and Wales.[1] In women, five-year survival has increased from 35% to 55% and then decreased to 46% over the same time periods.

Bladder Cancer (C67), Age-Standardised Five-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year survival for 2010-2011 is predicted using an excess hazard statistical model

Ten-year age-standardised net survival for bladder cancer in men has increased from 34% during 1971-1972 to 54% during 1990-1991 and remained stable at a predicted survival of 54% during 2010-2011 in England and Wales.[1] In women, ten-year survival has increased from 29% to 49% and then decreased to 40% over the same time periods. Overall, half of people diagnosed with bladder cancer today are predicted to survive their disease for at least ten years.

Bladder Cancer (C67), Age-Standardised Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model

See also

Bladder cancer incidence trends over time statistics

Bladder cancer mortality trends over time statistics

Cancer survival trends over time for all cancers

References

  1. Data were provided by London School of Hygiene and Tropical Medicine on request 2014.

About this data

Data is for England and Wales, 1971-2011, ICD-10 C67

Last reviewed:

Survival for bladder cancer is strongly related to stage of the disease at diagnosis.

One-year net survival by stage

One-year net survival for bladder cancer is highest for patients diagnosed at Stage 1, and lowest for those diagnosed at Stage 4, as 2013-2017 data for England show.[1] 95% of patients diagnosed at Stage 1 survived their disease for at least one year, compared to 36% of patients diagnosed at Stage 4.[1]

One year net survival for unknown or missing stage is 62%. Lack of staging information may in some cases reflect advanced stage at diagnosis as very unwell patients may not undergo staging tests if the invasiveness of the testing outweighs the potential benefit of obtaining stage information. Incomplete staging assessment may also be associated with socio-demographic and clinical characteristics of the patient [2]. Stage completeness for bladder cancer was 84% in 2013-2017 [1].

For patients diagnosed at Stages 1 to 4, one-year net survival is significantly lower for females than for males. At Stage 3 there is a survival difference of 11 percentage points between females and males. [1]

Bladder cancer one-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)

Five-year net survival by stage

There is limited data available to compare male and female 5-year survival. Five-year net survival for bladder cancer shows a significant decrease for males from Stage 1 to Stage 2, a difference of over 30 percentage points. [1]

Bladder cancer five-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)

References 

1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.
2. Girolamo, C. et al, Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with a colon, lung or breast cancer in England in 2013, BMC Cancer (2018) 18:492

About this data 

Data is for: England, 2013 - 2017, ICD-10 C67.

Survival statistics give an overall picture of survival but the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year relative survival for bladder cancer in men in England (74%) is above the average for Europe (69%). Wales (74%) and Northern Ireland (79%) are also above the European average but Scotland (53%) is below the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 53% (Scotland) to 79% (Malta).[1]

Five-year relative survival for bladder cancer in women in England (67%) is similar to the average for Europe (66%). Wales (67%) and Northern Ireland (70%) are also similar to the European average but Scotland (42%) is below to the European average.[1] Across the European countries for which data is available, five-year relative survival in women ranges from 42% (Scotland) to 77% (Italy).[1] 

Bladder Cancer (C67), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

See also

Cancer diagnosis and treatment

Bladder cancer incidence

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, bladder cancer (International Classification of Diseases for Oncology [ICD-O-3] C67).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Cancer stats explained

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

 @CRUKHCPs